A detailed history of Charles Schwab Investment Management Inc transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 264,494 shares of PHAT stock, worth $2.71 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
264,494
Previous 262,524 0.75%
Holding current value
$2.71 Million
Previous $2.4 Million 17.2%
% of portfolio
0.0%
Previous 0.0%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 08, 2024

BUY
$6.21 - $11.05 $12,233 - $21,768
1,970 Added 0.75%
264,494 $2.81 Million
Q4 2023

Feb 06, 2024

BUY
$6.99 - $10.71 $110,742 - $169,678
15,843 Added 6.42%
262,524 $2.4 Million
Q3 2023

Nov 08, 2023

BUY
$10.26 - $15.7 $695,740 - $1.06 Million
67,811 Added 37.91%
246,681 $2.56 Million
Q2 2023

Aug 09, 2023

BUY
$7.28 - $14.32 $52,874 - $104,006
7,263 Added 4.23%
178,870 $2.56 Million
Q1 2023

May 11, 2023

SELL
$6.19 - $12.36 $10,194 - $20,356
-1,647 Reduced 0.95%
171,607 $1.23 Million
Q4 2022

Feb 13, 2023

BUY
$9.18 - $11.53 $152,149 - $191,098
16,574 Added 10.58%
173,254 $1.94 Million
Q3 2022

Nov 14, 2022

BUY
$6.46 - $12.11 $238,154 - $446,447
36,866 Added 30.77%
156,680 $1.74 Million
Q2 2022

Aug 15, 2022

SELL
$6.2 - $15.5 $39,512 - $98,781
-6,373 Reduced 5.05%
119,814 $1.01 Million
Q1 2022

May 13, 2022

BUY
$11.55 - $20.06 $33,356 - $57,933
2,888 Added 2.34%
126,187 $1.72 Million
Q4 2021

Feb 11, 2022

BUY
$17.83 - $33.15 $43,291 - $80,488
2,428 Added 2.01%
123,299 $2.43 Million
Q3 2021

Nov 16, 2021

BUY
$30.69 - $36.83 $422,018 - $506,449
13,751 Added 12.84%
120,871 $3.88 Million
Q2 2021

Aug 16, 2021

BUY
$32.66 - $39.87 $648,758 - $791,977
19,864 Added 22.77%
107,120 $3.63 Million
Q1 2021

May 17, 2021

BUY
$33.86 - $48.68 $384,581 - $552,907
11,358 Added 14.96%
87,256 $3.28 Million
Q4 2020

Feb 16, 2021

BUY
$33.22 - $50.26 $3,687 - $5,578
111 Added 0.15%
75,898 $2.52 Million
Q3 2020

Nov 13, 2020

SELL
$29.24 - $40.19 $171,960 - $236,357
-5,881 Reduced 7.2%
75,787 $2.78 Million
Q2 2020

Aug 14, 2020

BUY
$25.06 - $54.6 $327,408 - $713,349
13,065 Added 19.04%
81,668 $2.69 Million
Q1 2020

May 15, 2020

BUY
$24.65 - $42.83 $20,114 - $34,949
816 Added 1.2%
68,603 $1.77 Million
Q4 2019

Feb 07, 2020

BUY
$18.59 - $37.67 $1.26 Million - $2.55 Million
67,787 New
67,787 $2.11 Million

Others Institutions Holding PHAT

About Phathom Pharmaceuticals, Inc.


  • Ticker PHAT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,175,200
  • Market Cap $402M
  • Description
  • Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...
More about PHAT
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.